Armodafinil
Nuvigil — sold as Waklert and Artvigil; the R-enantiomer of modafinil
Armodafinil (Nuvigil — sold as Waklert and Artvigil; the R-enantiomer of modafinil) is a cognitive & mood research compound. The R-enantiomer of modafinil, which is a 1:1 racemate. The eugeroic action is taken to be dopamine transporter blockade, but that was measured on the racemate and no imaging study of this enantiomer alone has ever been published. R-modafinil's half-life is about three times S-modafinil's, so an enantiopure tablet delivers the slow-clearing half alone — the label reports 50mg of armodafinil giving a concentration-time profile nearly superimposable on 100mg of modafinil. Amide hydrolysis is the dominant metabolic route with sulfone formation by CYP3A4/5 next; under 10% leaves as parent drug in urine. Induces CYP3A4, inhibits CYP2C19.
Armodafinil quick facts
| Route | Oral |
| Frequency | 1x Daily · Per prescription |
| Half-life | ~15 hrs (apparent terminal) |
| Forms | Oral |
| Evidence level | FDA-approved for obstructive sleep apnea, narcolepsy and shift work disorder — Schedule IV controlled substance |
Prescription-only and Schedule IV in the US. It is not a different drug from modafinil so much as half of it sold whole, and the evidence base treats it that way: the largest network meta-analysis in obstructive sleep apnea pools armodafinil and modafinil into one treatment node because there is no basis for separating them. Its own pivotal trials moved Maintenance of Wakefulness Test sleep latency 3.2 to 4.5 minutes over placebo. One asymmetry is worth knowing: the armodafinil label states physical dependence can occur and lists withdrawal symptoms by name, while the modafinil label reports none over 14 days of observation.
How Armodafinil works
The R-enantiomer of modafinil, which is a 1:1 racemate. The eugeroic action is taken to be dopamine transporter blockade, but that was measured on the racemate and no imaging study of this enantiomer alone has ever been published. R-modafinil's half-life is about three times S-modafinil's, so an enantiopure tablet delivers the slow-clearing half alone — the label reports 50mg of armodafinil giving a concentration-time profile nearly superimposable on 100mg of modafinil. Amide hydrolysis is the dominant metabolic route with sulfone formation by CYP3A4/5 next; under 10% leaves as parent drug in urine. Induces CYP3A4, inhibits CYP2C19.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Where to get Armodafinil
Buy Armodafinil at RUPharma →The R-enantiomer of modafinil, and the same schedule and the same three approved indications. The 150 mg tablet is the dose the trials used.
Same CYP3A4 induction as modafinil, and the same reason to know your hormone numbers if you are running anything. The longer effective half-life is why the afternoon dose is the one that costs you sleep.
Order these through my Marek link →The evidence for Armodafinil
Graded by what exists behind each claim.
✅ Clinically validated
- FDA-approved, Schedule IV, for the same three indications as modafinil, at 150 mg or 250 mg once daily. The pivotal trials moved Maintenance of Wakefulness Test sleep latency by +1.3 to +2.6 minutes against placebo changes of -1.3 to -1.9 minutes — a drug-placebo gap of 3.2 to 4.5 minutes, printed in the label's own efficacy table.
- The evidence base cannot separate it from modafinil. The 14-trial, 3085-patient network meta-analysis entered the two as a single treatment node (Pitre 2023). Later syntheses compared them only indirectly (Ronnebaum 2021; Tanayapong 2025) — because no head-to-head randomized trial exists.
📊 Correlative data
- The label reports that 50 mg of armodafinil gives an R-enantiomer concentration-time profile nearly superimposable on 100 mg of modafinil. That is the clearest statement anywhere that this is not a second drug.
- Community use mirrors modafinil's, with the reported difference being a smoother, later-running day. Consistent with R-modafinil's roughly three-fold longer half-life, and never tested against it.
🧪 Theoretical / extrapolated
- No positron-emission study has ever imaged this enantiomer. Every transporter number attributed to it belongs to the racemate, and the inference assumes the S-enantiomer contributed nothing — which nobody has checked.
- The largest practical difference from modafinil is a food effect: peak concentration is delayed 2 to 4 hours when taken fed, against about one hour for modafinil. That predicts more day-to-day variability from meal timing than from dose.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Armodafinil actually does
This is not a new molecule. It is half of an old one, sold whole. Nuvigil label 2025 opens the question and closes it in the same sentence: “Armodafinil is the R-enantiomer of modafinil which is a 1:1 mixture of the R- and S-enantiomers.” The same document then does the arithmetic for you: “The concentration-time profiles of the R-enantiomer following administration of a single-dose of 50 mg NUVIGIL or 100 mg PROVIGIL … are nearly superimposable.” Fifty milligrams of one equals a hundred of the other, for the half that matters. Nothing has been added; something has been removed.
What was removed, and why anybody bothered. The two halves do not clear at the same rate. Provigil label 2025 states that R-modafinil's half-life is approximately three times that of S-modafinil in adult humans. So a racemic tablet delivers a fast component that is gone by early afternoon and a slow component that carries the evening, while an R-only tablet delivers the slow component alone. That is the whole pharmacological argument for the enantiopure product: a flatter late-day curve at the same nominal morning exposure. It is a real argument. It is also a small one, and no trial has been designed to detect it.
The target is borrowed, and it has to be, because nobody has imaged this enantiomer. The transporter work in a living human was done on the racemate: 200 to 400 mg in 10 healthy men, [11C]cocaine binding potential down 39.3% to 53.8% across striatal regions Volkow 2009. No positron-emission study has ever been published for armodafinil alone, so its occupancy is inferred from the racemate's, and the inference is only as good as the assumption that the S-enantiomer contributed nothing to the picture — an assumption nobody has tested. Hersey 2024 treats the family as one atypical, weak transporter inhibitor with additional actions across GABA, glutamate, serotonin and noradrenaline.
Cell, rodent, human — and where it stops
Go straight to the regulator's efficacy table, because it is the most deflating document in this category and almost nobody reads it. Nuvigil label 2025 prints the Maintenance of Wakefulness Test change from baseline in the three pivotal trials. In the first sleep apnea trial: +1.7 minutes at 150 mg, +2.2 minutes at 250 mg, −1.7 minutes on placebo. Second apnea trial: +2.3 minutes at 150 mg against −1.3 on placebo. Narcolepsy: +1.3 minutes at 150 mg, +2.6 at 250 mg, −1.9 on placebo. Those are the numbers that won the approval. Subtract them and the drug-placebo gap is 3.2 to 4.5 minutes of sleep latency, which is a genuine, statistically defended result in a population that falls asleep at a desk. It is not the effect the word eugeroic conjures.
The field's own verdict on whether this differs from modafinil is written into the shape of its meta-analyses. Pitre 2023 pooled 14 trials and 3085 patients and entered armodafinil and modafinil as a single treatment node — “armodafinil-modafinil” — because there was no basis for separating them: Epworth mean difference −2.25 (95% CI −2.85 to −1.64), MWT standardized mean difference 0.41 (0.27 to 0.55), discontinuation for adverse events relative risk 2.01 (1.14 to 3.51). When a network meta-analysis collapses two products into one node, that is the evidence base saying it cannot tell them apart.
Two later syntheses looked specifically for a difference. Ronnebaum 2021 ran an indirect treatment comparison of solriamfetol, modafinil and armodafinil in apnea-associated daytime sleepiness; Tanayapong 2025 network-meta-analyzed multiple wake-promoting agents in the narrower and more useful population of residual sleepiness that persists despite continuous positive airway pressure. Both are indirect comparisons, which is the methodological point: the head-to-head randomized trial they are substituting for does not exist.
Where it stops, and it stops in the same place modafinil does. Every number above comes from people with a diagnosed sleep disorder. There is no randomized trial of armodafinil in rested adults for any purpose, and there is no published pharmacokinetic or imaging study of the 150 mg tablet in that population. A partner sells this at $23 to $25 for ten tablets alongside seven modafinil SKUs; the reason to prefer it, on the published evidence, is the three-fold-longer enantiomer half-life and nothing else.
Armodafinil pharmacokinetics — how much of it actually gets in
What degrades it, in order of importance. Nuvigil label 2025 is unusually specific: “Amide hydrolysis is the single most prominent metabolic pathway, with sulfone formation by cytochrome P450 (CYP) 3A4/5 being next in importance.” Less than 10% of the parent compound appears in urine, and plasma protein binding is about 60%, mainly albumin. Amidase chemistry first, a cytochrome second, the kidney barely at all.
The oral barrier and the one number that differs from the racemate. Peak plasma concentrations arrive at approximately 2 hours in the fasted state, and food delays that peak by 2 to 4 hours Nuvigil label 2025 — against about one hour for modafinil Provigil label 2025. That is the largest practical difference between the two products and it is a food effect, not a pharmacodynamic one: taken with breakfast, this drug's onset can land in the early afternoon. Apparent terminal half-life is approximately 15 hours. No injectable form exists; absorption is not the constraint for a neutral small molecule of this kind, and an injection would change nothing but the tmax.
The arithmetic of the enantiomer argument, done properly. If R-modafinil's half-life is three times S-modafinil's Provigil label 2025, then by roughly six hours after a racemic dose the S component has fallen through two of its own half-lives while the R component has barely completed one. Which means the late-day exposure from a 200 mg racemic tablet is already almost entirely R. The enantiopure product's advantage is therefore concentrated in the first few hours, not the last — the opposite of how it is usually sold — and it is best described as a cleaner early curve rather than a longer one.
The interaction profile is the racemate's, and one line of it matters more than the rest. Armodafinil induces CYP3A4 and inhibits CYP2C19. Nuvigil label 2025: “The effectiveness of steroidal contraceptives may be reduced when used with NUVIGIL and for one month after discontinuation of therapy.” On the other side, elimination of phenytoin, diazepam, propranolol, omeprazole and clomipramine may be prolonged, with higher systemic exposure. Identical wording to the modafinil label, for the identical reason.
What would have to be true, and how you would know it was not
Four predictions. The first is the one that would embarrass the product category.
1. Against the product: a head-to-head against modafinil will show nothing. Randomize 150 mg armodafinil against 200 mg modafinil, Maintenance of Wakefulness Test as the primary endpoint, in residual sleepiness on continuous positive airway pressure. Prediction: no difference the trial can detect. The basis is that Pitre 2023 already pooled them as one node, and the label's own superimposable-profile statement says 50 mg of one is 100 mg of the other for the R-enantiomer Nuvigil label 2025. This trial has never been run, and if it came back positive it would overturn the way the entire evidence base is currently assembled.
2. The size of any real effect is three minutes, and objective measurement will say so. A polysomnograph laboratory can run a Maintenance of Wakefulness Test; the drug-placebo gap in the pivotal trials was 3.2 to 4.5 minutes depending on the trial and dose Nuvigil label 2025. Anyone reporting a transformation should measure it, because the instrument that produced the approval is the instrument that would show it.
3. Actigraphy will detect the food effect before the reader does. Two matched weeks, same 07:00 dose, one taken fasted and one with a full breakfast, sleep tracker on throughout. Prediction from the 2-to-4-hour fed tmax delay Nuvigil label 2025: the fed week shifts both the onset of alertness and the delay in sleep onset later by a measurable amount. Almost nobody controls for this, and it is a more likely explanation for an inconsistent day than dose tolerance.
4. Stopping abruptly after chronic use will produce something, and the two labels disagree about what. Track resting heart rate and a symptom diary across a deliberate taper. Nuvigil label 2025 predicts shaking, sweating, chills, nausea, vomiting, confusion, aggression and atrial fibrillation on abrupt cessation; Provigil label 2025 predicts nothing beyond returning sleepiness. Both cannot be right about the same chemistry, and a structured self-report across a taper is the only measurement anybody outside a trial can contribute to the question.
What nobody has tested yet
Nobody has imaged this enantiomer in a human brain. Every occupancy figure on this page belongs to the racemate Volkow 2009. Repeating that protocol with armodafinil would answer a question the whole product depends on: does the R-enantiomer carry all of the transporter effect, or was the S-enantiomer doing part of the work? Ten volunteers and an existing radioligand.
The S-enantiomer has never been given to anybody on its own. That is the missing control for the entire enantiopure argument. If S-modafinil alone turned out to be inert, the case for armodafinil gets stronger; if it turned out to be responsible for a share of the wakefulness or a share of the side effects, the case changes shape entirely. Fifty years of this molecule and the obvious arm was never run.
The combination tablet on the shelf has no evidence behind it of any kind. One partner sells a 250 mg tablet described as modafinil plus armodafinil in one pill. Pharmacologically that is a racemate with extra R added, which is a mixture you can reach by taking more of either single product; there is no published trial, pharmacokinetic study or rationale for the ratio, and no reason to expect the combination behaves as anything other than the sum. Naming it here is the honest alternative to pretending it is a distinct compound with a page of its own.
Extrapolation, labeled as such. If the food effect on tmax is really 2 to 4 hours Nuvigil label 2025, then a meaningful share of the inconsistency people report on this drug is prandial rather than pharmacological, and a fed-versus-fasted crossover with a wakefulness endpoint would show it. Nobody has published one. It is a small study, it needs no new drug, and it would answer more day-to-day questions than another indirect comparison.
Armodafinil — its own safety story, not its class's
Three things this drug owns that its racemic parent does not say the same way.
The withdrawal divergence, and it is the sharpest fact on this page. Nuvigil label 2025 states that physical dependence can occur and that abrupt cessation or dose reduction after chronic use can produce shaking, sweating, chills, nausea, vomiting, confusion, aggression and atrial fibrillation. It also records abuse in treated patients, with escalating doses and recurrent use for a desired effect. Provigil label 2025, for the molecule that contains this one, says no withdrawal symptoms were reported during 14 days of observation, only returning sleepiness. Two FDA-approved labels from the same manufacturer, describing the same chemistry, reaching opposite conclusions. The 14-day observation window is the likely reconciliation and it is also the reason the older statement should not be leaned on.
The cutaneous and hypersensitivity risk is shared and is stated on this label in its own words. Serious rash requiring hospitalization and discontinuation has been reported with either drug; the incidence of rash leading to discontinuation in pediatric trial participants under 17 was approximately 0.8%, 13 per 1,585; angioedema and hypersensitivity with rash, dysphagia and bronchospasm have been observed; and one fatal case of DRESS occurred in close temporal association — 3 weeks — with starting treatment in postmarketing reporting Nuvigil label 2025. Three weeks is late enough that people have stopped connecting a new symptom to a new drug.
The legal status, and what it means for the rest of this page. Armodafinil is a prescription drug and a Schedule IV controlled substance in the United States Nuvigil label 2025. Nothing here is guidance for obtaining or using it without one. The fair summary of the evidence above is that this is modafinil's long-lived half, that its approval rests on a three-to-four-minute sleep-latency gap in people with diagnosed sleep disorders, that the largest synthesis in the field cannot distinguish it from the racemate, and that its own label carries the more serious dependence language of the two.
Sources read for this page
- U.S. Food and Drug Administration. NUVIGIL (armodafinil) tablets, C-IV - full prescribing information, including the Maintenance of Wakefulness Test results from the three pivotal trials and the physical dependence and withdrawal statements. DailyMed, U.S. National Library of Medicine; Cephalon LLC label version 32, revised May 2025
- U.S. Food and Drug Administration. PROVIGIL (modafinil) tablets, C-IV - full prescribing information, including the serious rash warning, the mechanism-of-action statement, the CYP3A4/5 induction and CYP2C19 inhibition sections and the drug abuse and dependence section. DailyMed, U.S. National Library of Medicine; Cephalon LLC label version 23, revised March 2025
- Pitre T. Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea: A Systematic Review and Network Meta-analysis. Annals of Internal Medicine 2023 · PMID 37155992
- Ronnebaum S. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea. Journal of Clinical Sleep Medicine 2021 · PMID 34402784
- Tanayapong P. Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Residual Sleepiness in Obstructive Sleep Apnea Despite Continuous Positive Airway Pressure: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. CNS Drugs 2025 · PMID 40208562
- Hersey M, Tanda G. Modafinil, an atypical CNS stimulant?. Advances in Pharmacology 2024;99:287-326 · PMID 38467484
- Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, Wang GJ, Jayne M, Hooker JM, Wong C, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301(11):1148-1154 · PMID 19293415
Armodafinil — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- This class is broad, but the predicted problems cluster by mechanism rather than by molecule. Cholinergics (racetams, and anything raising acetylcholine) predict headache — the classic one, from choline demand outrunning supply. Dopaminergics and eugeroics predict tolerance, sleep disruption and a flat mood on the days off. Anything glutamatergic or AMPA-facing carries a theoretical excitotoxicity concern at high doses.
- The pattern worth internalizing: anything that borrows performance from tomorrow eventually presents the bill. Sleep is the most common currency it gets paid in.
What has actually been reported
- Headache is the most reported effect across the racetam family and usually responds to added choline.
- Irritability, blunted affect and a rebound low on cessation are commonly reported with the stimulant-adjacent members.
- Most of this class has little or no controlled human safety data at the doses actually used.
How to reduce the risk
Same mechanism as the prediction.
- Take a choline source with any racetam. The headache is the mechanism running out of substrate, and it is largely preventable rather than something to push through.
- Dose in the morning. Almost everything in this class has a longer functional tail than its half-life suggests, and sleep is the first thing you lose.
- Use them for something, not as a habit. The compounds that carry tolerance genuinely reward intermittent use aimed at a task, and genuinely punish daily use aimed at feeling normal.
- One at a time, and long enough to judge it. This is the class where people stack five and cannot tell you which one is doing anything — and the effects are subjective, so attribution is already hard enough.
- If you need it to feel normal, stop. That is the line where a tool has become a dependency, and it is the one worth watching for.
What it does to your bloodwork
A fact about the assay.
- No routine marker tracks these. Sleep is the assay — if it is degrading, the compound is costing more than it is producing, and that shows up before anything else does.
Don't run this if
- A seizure history — several of these lower the threshold at least theoretically, and it is not worth establishing empirically.
- Bipolar disorder, for the dopaminergic members especially.
- Alongside prescribed psychiatric medication without knowing exactly how the mechanisms overlap.
The honest unknown
- Chronic use is essentially uncharacterized. The specific unmeasured thing is what daily cholinergic or dopaminergic pressure does to baseline function over years — not whether a few weeks is tolerable.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Armodafinil — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Armodafinil moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Armodafinil in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Armodafinil
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Armodafinil — frequently asked questions
What is Armodafinil?
Armodafinil (Nuvigil — sold as Waklert and Artvigil; the R-enantiomer of modafinil) is a cognitive & mood research compound. The R-enantiomer of modafinil, which is a 1:1 racemate. The eugeroic action is taken to be dopamine transporter blockade, but that was measured on the racemate and no imaging study of this enantiomer alone has ever been published. R-modafinil's half-life is about three times S-modafinil's, so an enantiopure tablet delivers the slow-clearing half alone — the label reports 50mg of armodafinil giving a concentration-time profile nearly superimposable on 100mg of modafinil. Amide hydrolysis is the dominant metabolic route with sulfone formation by CYP3A4/5 next; under 10% leaves as parent drug in urine. Induces CYP3A4, inhibits CYP2C19.
Where can I find Armodafinil dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Armodafinil protocol are available to members inside Skool. This public page covers what Armodafinil is, how it works and the evidence.
What is the half-life of Armodafinil?
Armodafinil has an approximate half-life of ~15 hrs (apparent terminal), which is part of what determines how often it's dosed.
What's the evidence behind Armodafinil?
Current evidence level: FDA-approved for obstructive sleep apnea, narcolepsy and shift work disorder — Schedule IV controlled substance. Armodafinil is offered for research purposes only and is not an approved medicine.
What Armodafinil is used for
Armodafinil appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.